Does the Number of Bifunctional Chelators Conjugated to a mAb Affect the Biological Activity of Its Radio-Labeled Counterpart? Discussion Using the Example of mAb against CD-20 Labeled with
Journal
Journal of medicinal chemistry
ISSN: 1520-4804
Titre abrégé: J Med Chem
Pays: United States
ID NLM: 9716531
Informations de publication
Date de publication:
12 05 2022
12 05 2022
Historique:
pubmed:
21
4
2022
medline:
18
5
2022
entrez:
20
4
2022
Statut:
ppublish
Résumé
There has been considerable interest in developing a monoclonal antibody (mAb) against-CD-20 (for example, Rituximab) modified by bifunctional chelating agents (BCA) for non-Hodgkin's lymphoma radioimmunotherapy. Therefore, many researchers have modified this monoclonal antibody by attaching different BCA moieties and evaluated their biological activities in terms of in vitro study and in vivo study in healthy and tumor xenografted rodents. This mini-perspective reviews the in vitro studies, the immunoreactivity and physiological distribution studies: organ-to-blood and the tumor-to-organ ratio of conjugates with different numbers of chelators per mAb. We set up a null hypothesis that states there is no statistical significance between the biological activity of monoclonal antibody (Rituximab) and the number of conjugated bifunctional chelators. Overall, we have concluded that there is no strong evidence for this hypothesis. However, the literature data should be questioned due to the potential lack of uniform study methodology.
Identifiants
pubmed: 35442675
doi: 10.1021/acs.jmedchem.1c02044
pmc: PMC9109692
doi:
Substances chimiques
Antibodies, Monoclonal
0
Chelating Agents
0
Radioisotopes
0
Rituximab
4F4X42SYQ6
Lutetium
5H0DOZ21UJ
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
6419-6430Références
Mol Biol Rep. 2018 Dec;45(6):2935-2940
pubmed: 30311129
Pharmacol Ther. 2018 Jan;181:76-84
pubmed: 28720430
J Immunol Methods. 1984 Aug 3;72(1):77-89
pubmed: 6086763
Anticancer Agents Med Chem. 2007 May;7(3):335-43
pubmed: 17504159
Oncogene. 2003 Dec 8;22(56):9097-106
pubmed: 14663488
J Am Chem Soc. 1965 Mar 5;87:1115-20
pubmed: 14284626
J Nucl Med. 1994 May;35(5):882-9
pubmed: 8176477
Ther Deliv. 2011 Mar;2(3):397-416
pubmed: 22834009
Cancer Biother Radiopharm. 2015 Aug;30(6):240-6
pubmed: 26066665
Bioconjug Chem. 1990 Jul-Aug;1(4):291-5
pubmed: 2096922
Antibodies (Basel). 2020 Jul 20;9(3):
pubmed: 32698317
Nucl Med Biol. 2006 Oct;33(7):883-9
pubmed: 17045168
Clin Cancer Res. 2012 Oct 1;18(19):5160-2
pubmed: 22912394
Drug Metab Dispos. 2014 Nov;42(11):1914-20
pubmed: 25048520
Indian J Med Res. 2016 Jan;143(1):57-65
pubmed: 26997015
Cancer Res. 1995 Feb 15;55(4):878-84
pubmed: 7850803
Eur J Nucl Med Mol Imaging. 2003 Feb;30(2):312-5
pubmed: 12552352
Curr Radiopharm. 2015;8(1):62-8
pubmed: 25506704
J Exp Med. 2005 Nov 21;202(10):1307-11
pubmed: 16301740
Nucl Med Biol. 2004 Aug;31(6):795-802
pubmed: 15246371
Iran J Pharm Res. 2017 Spring;16(2):619-629
pubmed: 28979315
Int J Cancer. 1995 Apr 10;61(2):286-8
pubmed: 7705960
Cancer Chemother Pharmacol. 2001 Aug;48 Suppl 1:S91-5
pubmed: 11587375
Eur J Nucl Med. 2001 Nov;28(11):1725-35
pubmed: 11702116
Front Oncol. 2017 Feb 20;7:22
pubmed: 28265553
Bioconjug Chem. 1992 Jul-Aug;3(4):342-5
pubmed: 1390990
Nature. 1985 Dec 12-18;318(6046):533-8
pubmed: 3906410
Int J Rad Appl Instrum B. 1991;18(8):859-64
pubmed: 1800461
J Immunol Methods. 1991 Nov 22;144(2):175-83
pubmed: 1960414
J Labelled Comp Radiopharm. 2019 Oct;62(12):850-859
pubmed: 31461549
Appl Radiat Isot. 2011 Jul;69(7):924-8
pubmed: 21474325
Cancer Biother Radiopharm. 2020 Oct;35(8):558-562
pubmed: 32255676
Curr Treat Options Oncol. 2002 Aug;3(4):275-82
pubmed: 12074764
Mol Imaging. 2015;14:400-13
pubmed: 26218718
J Pharmacol Exp Ther. 2009 Sep;330(3):932-8
pubmed: 19498104
J Biomed Sci. 2017 Feb 20;24(1):15
pubmed: 28219375
Semin Nucl Med. 2005 Jul;35(3):202-11
pubmed: 16098294
Drug Discov Today. 2001 May 1;6(10):517-528
pubmed: 11369291
Leuk Lymphoma. 2014 Sep;55(9):2151-5160
pubmed: 24304419
Angiogenesis. 2020 Nov;23(4):515-529
pubmed: 32451774
Indian J Med Res. 2014 Apr;139(4):544-54
pubmed: 24927340
PLoS One. 2013;8(4):e60350
pubmed: 23565233
Nucl Med Biol. 1999 Nov;26(8):977-82
pubmed: 10708314
Clin Cancer Res. 2011 Apr 15;17(8):2207-15
pubmed: 21385922
Anticancer Agents Med Chem. 2018;18(1):146-153
pubmed: 28745238
Int J Rad Appl Instrum A. 1992 Aug;43(8):961-7
pubmed: 1330982
Cell. 2015 Sep 24;163(1):39-53
pubmed: 26406370
Int J Rad Appl Instrum B. 1991;18(4):389-94
pubmed: 1864727
Curr Radiopharm. 2013 Mar;6(1):20-7
pubmed: 23256748
Daru. 2014 Jul 29;22:58
pubmed: 25074720
Cancer Biother Radiopharm. 2004 Dec;19(6):706-15
pubmed: 15665617
Nucl Med Biol. 1998 Feb;25(2):117-25
pubmed: 9468026
Iran J Pharm Res. 2018 Fall;17(4):1201-1208
pubmed: 30568680
Am J Physiol Heart Circ Physiol. 2020 Mar 1;318(3):H726-H728
pubmed: 32141767
Tumour Biol. 1991;12(4):198-206
pubmed: 1651554
MAbs. 2013 Jan-Feb;5(1):22-33
pubmed: 23211638
N Engl J Med. 2012 May 24;366(21):2008-16
pubmed: 22621628
Leukemia. 2017 Jul;31(7):1611-1621
pubmed: 27890931
Chem Rev. 2015 Apr 22;115(8):2934-74
pubmed: 25865818
Bioconjug Chem. 1995 May-Jun;6(3):313-5
pubmed: 7632804
Semin Oncol. 2003 Dec;30(6 Suppl 17):1-5
pubmed: 14710396
Blood. 2009 Apr 16;113(16):3765-72
pubmed: 19029438
Eur J Nucl Med Mol Imaging. 2009 Sep;36(9):1443-52
pubmed: 19350237
Clin Cancer Res. 2007 Jan 15;13(2 Pt 1):603-11
pubmed: 17255283
Blood. 2004 Mar 15;103(6):2276-83
pubmed: 14630790
J Exp Clin Cancer Res. 2019 Apr 11;38(1):156
pubmed: 30975211
Proc Natl Acad Sci U S A. 2015 Oct 20;112(42):13081-6
pubmed: 26438862
Nat Rev Drug Discov. 2012 May;11(5):401-19
pubmed: 22543469